Quantcast

Latest Apolipoproteins Stories

2014-10-01 20:24:10

Data From Phase 3 RUTHERFORD-2 Study Show Evolocumab Significantly Reduced Mean LDL-C by 59-66 Percent Compared to Placebo in Patients With Heterozygous Familial Hypercholesterolemia THOUSAND OAKS, Calif., Oct. 1, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced The Lancet published data from two Phase 3 studies, RUTHERFORD-2 and TESLA, that showed treatment with evolocumab, a novel investigational low-density lipoprotein cholesterol (LDL-C)-lowering medication, resulted in...

2014-09-30 23:11:18

GIA announces the release of a comprehensive global report on Cholesterol Testing markets. Global market for Cholesterol Testing is projected to reach 2.9 billion tests by 2020, driven by the surge in health conditions such as diabetes, obesity and hypertension. San Jose, California (PRWEB) September 30, 2014 Follow us on LinkedIn –Cholesterol tests generally measure the level of each type of cholesterol carrier or lipoprotein in the blood. Such tests are essential since the presence of...

2014-09-02 08:30:49

Presented in 'State of the Art and Featured Research Session' at the 2014 European Society of Cardiology Congress TSX Exchange Symbol: RVX BARCELONA, Spain and CALGARY, AB, Sept. 2, 2014 /PRNewswire/ - Resverlogix Corp. (TSX: RVX) announced today that Dr. Jan Johansson, senior vice president of medical affairs at Resverlogix delivered an oral presentation at the 2014 European Society of Cardiology (ESC) Congress in Barcelona, Spain. In his presentation, entitled: 'Effects of...

2014-07-17 08:28:35

CARLSBAD, Calif., July 17, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the initiation of a Phase 2 study evaluating ISIS-APO(a)(Rx) in patients with high lipoprotein(a), or Lp(a), an independent risk factor for cardiovascular disease. Patients with high levels of Lp(a) have an increased risk of atherosclerosis, coronary heart disease, aortic stenosis, heart attack and stroke. ISIS-APO(a)(Rx) is designed to reduce Lp(a) by inhibiting the production of...

Exercise Keeps Hippocampus Healthy In People At Risk For Alzheimer's Disease
2014-04-23 15:09:22

University of Maryland Maintaining hippocampus volume is key to delaying cognitive decline and onset of dementia symptoms in those with genetic risk for Alzheimer's A study of older adults at increased risk for Alzheimer's disease shows that moderate physical activity may protect brain health and stave off shrinkage of the hippocampus– the brain region responsible for memory and spatial orientation that is attacked first in Alzheimer's disease. Dr. J. Carson Smith, a kinesiology...

2014-03-31 12:29:54

"RVX-208 decreases Major Adverse Cardiac Events (MACE) in patients with systemic inflammation" TSX Exchange Symbol: RVX CALGARY, March 31, 2014 /PRNewswire/ - Resverlogix Corp. (TSX: RVX) today announced that ASSURE data will be presented at the ACC conference in Washington DC. The poster titled "Effects of an Apolipoprotein A-1 Inducer on Progression of Coronary Atherosclerosis and Cardiovascular Events in Patients with Elevated Inflammatory Markers" will be presented by...

2014-03-31 12:28:14

Data demonstrates that the NMR LipoProfile® test provides clinically reliable information to help reduce cardiovascular events, especially in patients with diabetes and those on statin therapy WASHINGTON, March 31, 2014 /PRNewswire/ -- LipoScience, Inc. (NASDAQ: LPDX), a diagnostic company pioneering a new field of personalized nuclear magnetic resonance (NMR) diagnostics to advance the quality of patient care in cardiovascular, metabolic and other diseases, today announced data showing that...

2014-03-29 16:20:11

Data From Three Separate Phase 3 Studies of Evolocumab (AMG 145), a PCSK9 Inhibitor, Presented as Featured Clinical Research at ACC.14 THOUSAND OAKS, Calif., March 29, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new detailed data from three Phase 3 studies that showed treatment with its novel investigational cholesterol-lowering medication, evolocumab (AMG 145), resulted in a statistically significant reduction of 55-66 percent in low-density lipoprotein cholesterol (LDL-C)...

2014-03-17 16:28:30

"European Patent Office Grants RVX-208 Patent Until 2027" "Resverlogix Receives $2.5 Million for Non-Core ApoA-I Assets" TSX Exchange Symbol: RVX CALGARY, March 17, 2014 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) is pleased to announce today that it has received confirmation that its European patent application covering RVX-208 has been granted. European Patent no. 2118074 is titled "Compounds for the prevention and treatment of...

2014-03-17 08:30:17

Study Meets Primary Endpoint of LDL Cholesterol Reduction THOUSAND OAKS, Calif., March 17, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Phase 3 TESLA (Trial Evaluating PCSK9 Antibody in Subjects with LDL Receptor Abnormalities) trial evaluating evolocumab met its primary endpoint of the percent reduction from baseline at week 12 in low-density lipoprotein cholesterol (LDL-C). The percent reduction in LDL-C, or "bad" cholesterol, was clinically meaningful and statistically...


Word of the Day
negawatt
  • A unit of saved energy.
Coined by Amory Lovins, chairman of the Rocky Mountain Institute as a contraction of negative watt on the model of similar compounds like megawatt.